Eli Lilly is progressing its experimental obesity and type 2 diabetes drug retatrutide into Phase 3 trials, following late-stage data showing significant weight loss and metabolic improvements. Retatrutide belongs to a new class of drugs known as triple agonists, targeting three key metabolic pathways simultaneously. In earlier trials, the drug demonstrated weight loss outcomes exceeding…